Helomics® to Attend the 2016 BIO International Convention

PITTSBURGH--()--Helomics Corporation, a privately held comprehensive personalized healthcare company that develops innovative next generation diagnostics for the oncology field, announced today that the company will attend the 2016 Biotechnology Innovation Organization (BIO) International Convention being held June 6 - 9, 2016, in San Francisco. Helomics will represent Pennsylvania’s life sciences industry at the gathering of 15,000 global biotechnology and pharma leaders.

Pennsylvania is home to more than 2,300 life sciences establishments, employing 78,000 people. The state also boasts 1,000 research, testing and medical labs, and is one of only six states with a tradable R&D tax credit. As a result, Pennsylvania leads the industry in key measures of research and development, venture capital and patenting. Pennsylvania is ranked fourth nationally in R&D expenditures, National Institutes of Health funding, and pharmaceuticals industry strength.

To support the state’s continued success in the life sciences industries, Helomics will exhibit its personalized tumor profiling tests, including ChemoFx, GeneFX, BioSpeciFx, CellFx and DEFENDER, at the Pennsylvania Pavilion, booth #1705.

The BIO International Convention is a four-day conference and the largest global event for the biotechnology industry, attracting some of the biggest names in biotech. At BIO, the global biotechnology community gathers, connecting the people, companies and innovations that help to fulfill the promise of biotechnology through healing, fueling, and feeding the world.

About Helomics® Corporation

Helomics® is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a comprehensive personalized tumor profile utilizing a proprietary set of laboratory platforms that leverage both live and fixed cellular analysis to allow physicians to personally characterize malignant tumors. Helomics’ novel molecular and cellular markers and bioinformatics services are designed to support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer.

Helomics is headquartered in Pittsburgh, Pennsylvania where the company maintains two CLIA-certified laboratories. For more information please visit: www.helomics.com.

Contacts

Tiberend Strategic Advisors, Inc.
Investors
Joshua Drumm, Ph.D., 212-375-2664
jdrumm@tiberend.com
or
Media
Claire Sojda, 212-375-2686
csojda@tiberend.com

Contacts

Tiberend Strategic Advisors, Inc.
Investors
Joshua Drumm, Ph.D., 212-375-2664
jdrumm@tiberend.com
or
Media
Claire Sojda, 212-375-2686
csojda@tiberend.com